-
公开(公告)号：US5506216A
公开(公告)日：1996-04-09
申请号：US231170
申请日：1994-04-22
申请人： Axel Schmidt , Herbert von der Eltz , Klaus Kaluza
发明人： Axel Schmidt , Herbert von der Eltz , Klaus Kaluza
IPC分类号： A61K9/08 , A01N25/10 , A01N25/22 , A01N31/08 , A01N47/48 , A61K47/40 , C08B37/00 , G01N33/52 , C08B37/16 , C09K15/04 , C12Q1/00 , C07K15/06
CPC分类号： A01N25/10 , C08B37/0015 , G01N33/52
摘要： The invention concerns a complex of cyclodextrin and an organic biocide, wherein the organic biocide has a maximum water-solubility of 0.15% (w/v) at a temperature of 25.degree. C., a process for the production of the complex as well as the use of the complex for preserving aqueous solutions. In addition the invention concerns a diagnostic test solution which contains at least one complex according to the invention and a preserved diagnostic test kit which comprises test reagents and at least one complex according to the invention.
摘要翻译： 本发明涉及环糊精和有机杀生物剂的复合物，其中有机杀生物剂在25℃的温度下具有0.15％（w / v）的最大水溶解度，生产复合物的方法以及 使用复合物保存水溶液。 此外，本发明涉及包含至少一种根据本发明的复合物的诊断测试溶液和包含测试试剂和至少一种根据本发明的复合物的保存的诊断测试试剂盒。
-
公开(公告)号：US08785153B2
公开(公告)日：2014-07-22
申请号：US13402399
申请日：2012-02-22
申请人： Georg Fertig , Jens Fischer , Guy Georges , Klaus Kaluza , Valeria Lifke , Joerg Moelleken , Sonja Offner , Achal Pashine , Stefan Seeber
发明人： Georg Fertig , Jens Fischer , Guy Georges , Klaus Kaluza , Valeria Lifke , Joerg Moelleken , Sonja Offner , Achal Pashine , Stefan Seeber
IPC分类号： C12P21/08
CPC分类号： C07K16/2866 , A61K39/395 , A61K39/39558 , A61K2039/505 , C07K2317/24 , C07K2317/30 , C07K2317/76 , C07K2317/92
摘要： An antibody binding to IL33R characterized in that the heavy chain variable domain comprises a CDR3 region of SEQ ID NO:1, a CDR2 region of SEQ ID NO:2 and a CDR1 region of SEQ ID NO:3 and in that the light chain variable domain comprises a CDR3 region of SEQ ID NO:4, a CDR2 region of SEQ ID NO:5 and a CDR1 region of SEQ ID NO:6 or a chimeric, humanized or T cell epitope depleted antibody variant thereof has advantageous properties for the treatment of inflammatory diseases.
摘要翻译： 结合IL33R的抗体，其特征在于重链可变结构域包含SEQ ID NO：1的CDR3区，SEQ ID NO：2的CDR2区和SEQ ID NO：3的CDR1区，并且其中轻链可变区 结构域包含SEQ ID NO：4的CDR3区，SEQ ID NO：5的CDR2区和SEQ ID NO：6的CDR1区或嵌合，人源化或T细胞表位缺失的抗体变体具有治疗的有利性质 的炎性疾病。
-
公开(公告)号：US20140065151A1
公开(公告)日：2014-03-06
申请号：US13548244
申请日：2012-07-13
申请人： Ulrich Brinkmann , Remko Albert Griep , Klaus Kaluza , Anita Kavlie , Christian Klein , Joerg Thomas Regula , Werner Scheuer
发明人： Ulrich Brinkmann , Remko Albert Griep , Klaus Kaluza , Anita Kavlie , Christian Klein , Joerg Thomas Regula , Werner Scheuer
IPC分类号： C07K16/22
CPC分类号： C07K16/22 , A61K39/00 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C12N15/85
摘要： The present invention relates to a method of treating a disease or disorder in a patient comprising administering, to a patient in need of such treatment, an antibody which binds specifically to human angiopoietin-2 (ANG-2). The present invention also relates to a method for preventing metastasis in a patient suffering from primary cancer comprising administering, to a patient in need of such preventative treatment, an antibody which binds specifically to human angiopoietin-2 (ANG-2).
摘要翻译： 本发明涉及治疗患者疾病或病症的方法，包括向需要这种治疗的患者施用特异性结合人血管生成素-2（ANG-2）的抗体。 本发明还涉及一种用于预防患有原发性癌症的患者转移的方法，包括向需要这种预防性治疗的患者施用特异性结合人血管生成素-2（ANG-2）的抗体。
-
公开(公告)号：US08399626B2
公开(公告)日：2013-03-19
申请号：US13358831
申请日：2012-01-26
申请人： Ulrich Brinkmann , Remko Albert Griep , Klaus Kaluza , Anita Kavlie , Christian Klein , Joerg Thomas Regula , Werner Scheuer
发明人： Ulrich Brinkmann , Remko Albert Griep , Klaus Kaluza , Anita Kavlie , Christian Klein , Joerg Thomas Regula , Werner Scheuer
CPC分类号： C07K16/22 , A61K39/00 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C12N15/85
摘要： The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
-
5.发明申请PYRIDONEAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS 审中-公开吡咯烷酮衍生物，其制造和用作药物代理公开(公告)号：US20110218199A1
公开(公告)日：2011-09-08
申请号：US12672332
申请日：2008-08-20
申请人： Guy Georges , Klaus Kaluza , Matthias Koerner , Ulrike Reiff , Stefan Scheiblich , Wolfgang Von Der Saal , Stefan Weigand
发明人： Guy Georges , Klaus Kaluza , Matthias Koerner , Ulrike Reiff , Stefan Scheiblich , Wolfgang Von Der Saal , Stefan Weigand
IPC分类号： A61K31/5377 , C07D413/02 , C07D401/02 , C07D211/68 , C07D213/78 , A61K31/497 , A61K31/4545 , A61K31/4412 , A61P35/00
CPC分类号： C07D213/82 , C07D401/12
摘要： Compounds of formula I are disclosed. These compounds are useful in the control or prevention of cancer.
摘要翻译： 公开了式I化合物。 这些化合物可用于控制或预防癌症。
-
公开(公告)号：US07956190B2
公开(公告)日：2011-06-07
申请号：US12600662
申请日：2008-06-23
申请人： Guy Georges , Eike Hoffmann , Klaus Kaluza , Matthias Koerner , Ulrike Reiff , Stefan Weigand
发明人： Guy Georges , Eike Hoffmann , Klaus Kaluza , Matthias Koerner , Ulrike Reiff , Stefan Weigand
IPC分类号： C07D401/00
CPC分类号： C07D401/14 , C07D401/04
摘要： Objects of the present invention are the compounds of formula (I) their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.
摘要翻译： 本发明的目的是式（I）化合物的药学上可接受的盐，对映体形式，非对映异构体和外消旋体，上述化合物的制备，含有它们的药物及其制备方法，以及上述用途， 提及的化合物在控制或预防诸如癌症的疾病中。
-
7.发明授权Heterocyclic carbamate derivatives, their manufacture and use as pharmaceutical agents 失效杂环氨基甲酸酯衍生物，其制造和用作药剂公开(公告)号：US07786113B2
公开(公告)日：2010-08-31
申请号：US11793750
申请日：2005-12-22
IPC分类号： A61K31/5377 , A61K31/44 , C07D413/14 , C07D471/02
CPC分类号： C07D471/04
摘要： Objects of the present invention are the compounds of formula I their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.
摘要翻译： 本发明的目的是式I化合物，其药学上可接受的盐，对映体形式，非对映异构体和外消旋物，上述化合物的制备，含有它们的药物及其制备，以及上述化合物 控制或预防癌症等疾病。
-
公开(公告)号：US5183747A
公开(公告)日：1993-02-02
申请号：US777759
申请日：1991-10-10
申请人： Klaus Kaluza , Bruno Frey , Michael Jarsch
发明人： Klaus Kaluza , Bruno Frey , Michael Jarsch
CPC分类号： C12N9/22
摘要： The new type II restriction endonuclease Ssp4800I has the following recognition sequence: ##STR1## and preferably cleaves at the cleavage site defined by the arrows. It is preferably obtainable from microorganisms of the genus Streptomyces.
摘要翻译： 新型II型限制性内切核酸酶Ssp4800I具有以下识别序列：
，并且优选在由箭头限定的切割位点处切割。 其优选可从链霉菌属的微生物获得。 -
公开(公告)号：US09221910B2
公开(公告)日：2015-12-29
申请号：US13582989
申请日：2011-03-03
申请人： Georg Fertig , Alexander Fidler , Klaus Kaluza , Marlene Thomas , Carola Ries , Stefan Seeber
发明人： Georg Fertig , Alexander Fidler , Klaus Kaluza , Marlene Thomas , Carola Ries , Stefan Seeber
IPC分类号： A61K39/395 , C07K16/28 , C12N5/12
CPC分类号： C07K16/2866 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
摘要翻译： 本发明涉及针对人CSF-1R（CSF-1R抗体）的抗体，其制备方法，含有所述抗体的药物组合物及其用途。
-
公开(公告)号：US20130005949A1
公开(公告)日：2013-01-03
申请号：US13582989
申请日：2011-03-03
申请人： Georg Fertig , Alexander Fidler , Klaus Kaluza , Marlene Thomas , Carola Ries , Stefan Seeber
发明人： Georg Fertig , Alexander Fidler , Klaus Kaluza , Marlene Thomas , Carola Ries , Stefan Seeber
IPC分类号： C07K16/28 , C12N15/13 , C12N15/63 , C12N1/21 , C07K16/30 , C12N5/10 , C12N1/19 , C07K16/46 , C12P21/02
CPC分类号： C07K16/2866 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
-
-
-
-
-
-
-
-
-
搜索结果
34 条记录 (耗时 0.033 秒)
